You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm's technology uses ex vivo organ culture to model cancer growth and predict a patient's tumor response to chemotherapy and targeted drugs.
The Rehovot, Israel-based precision medicine firm will use the funding to scale clinical trials and expansion to the UK.
A new microbiome analysis uncovered cancer type-specific bacterial community features, along with intracellular bacteria in tumor and associated immune cells.
In Nature this week: new study of the Wuhan coronavirus suggests bats as the source of the outbreak, bioinformatic approach to identify cancer driver genes, and more.
Weizmann Institute of Science researchers have developed an Escherichia coli strain that consumes carbon dioxide, Discover magazine reports.
In Cell this week: microinjection of CRISPR-Cas9 enables targeted mutations in Anolis, melanoma proteomic profiling, and more.
Researchers identified tumor microbe and immune differences in tumor samples from pancreatic ductal adenocarcinoma patients with exceptionally long survival.
With gut metagenomic sequences from two population cohorts, investigators identified associations between health traits and microbial structural variants.
In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.
Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.
In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.